-
Delgado D, Gascón AR, del Pozo-Rodríguez A, Echevarria E, Ruiz de Garibay AP, Rodríguez JM, Solinís MA
Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: In vitro characterization and in vivo transfection after intravenous administration to mice
International Journal of Pharmaceutics,
2012;
425,
35 - 43
-
Delgado D, del Pozo-Rodríguez A, SolinísMA, Avilés M, Weber BH, Fernández E, Rodríguez-Gascón A
Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X linked juvenile retinoschisis
Human Gene Therapy,
2012;
23,
355
-
Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM, Solinís MÁ, Gascón AR
Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery
European Journal of Clinical Pharmacology,
2012;
68,
735 - 745
-
Canut A, Isla A, Betriu C, Rodríguez-Gascón A.
Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline and linezolid versus vancomycin for the treatment of MRSA infections in several Western European countries
European Journal of Clinical Microbiology & Infectious Diseases,
2012;
31,
2227 - 2235
-
Asín E, Isla A, Canut A, Rodríguez-Gascón A.
Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria
International Journal of Antimicrobial Agents,
2012;
40,
313 - 322
-
Ruiz de Garibay AP, Delgado D, del Pozo-Rodríguez A, Solinís MA, Gascón AR
Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy
Drug Design, Development and Therapy,
2012;
6,
303 - 310
-
Calvo B, Zuñiga L.
The US approach to biosimilars: the long-awaited FDA approval pathway
BioDrugs,
2012;
26,
357 - 361
-
Calvo B, Zuñiga L.
Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development
Current Medicinal Chemistry,
2012;
19,
4445 - 4450
